High-dose daptomycin in documented Staphylococcus aureus infections

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 459-461

  Bassetti, Matteo ^a   Nicco, Elena ^a   Ginocchio, Francesca ^a   Ansaldi, Filippo ^a   de Florentiis, Daniela ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Bacteraemia; CPK; Daptomycin; High dose; Staphylococcus aureus

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ADULT; AGED; ANEMIA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOKALEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 77957658501     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.07.011     Document Type: Article

References (15)

1. DeRyke C.A., Sutherland C., Zhang B., Nicolau D., Kuti J.L. Serum bactericidal activities of high-dose daptomycin with and without co-administration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother 2006, 50:3529-3534.
2. 2+ and albumin on these drugs. Antimicrob Agents Chemother 1991, 35:1710-1716.
3. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681. Daptomycin 98-01 and 99-01 Investigators.
4. Fowler V.G., Boucher H.W., Corey R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
5. Boucher H.W., Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007, 45:601-608.
6. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006, 44:655-656.
7. Rose W.E., Rybak M.J., Kaatz G.W. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007, 60:334-340.
8. Benvenuto M., Benziger D.P., Yankelev S., Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006, 50:3245-3249.
9. Cunha B.A., Eisenstein L.E., Hamid N.S. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 2006, 35:207-211.
10. Cunha B.A., Krol V., Kodali V. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job' syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2008, 37:72-75.
11. Katz D.E., Lindfield K.C., Steenbergen J.N., Benziger D.P., Blackerby K.J., Knapp A.G., et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria. Int J Clin Pract 2008, 62:1455-1464.
12. Moise P.A., Hershberger E., Amodio-Groton M.I., Lamp K.C. Safety and clinical outcomes when utilizing high-dose (≥8mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43:1211-1219.
13. Figueroa D.A., Mangini E., Amodio-Groton M., Vardianos B., Melchert A., Fana C., et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009, 49:177-180.
14. Murillo O., Garrigós C., Pachón M.E., Euba G., Verdaguer R., Cabellos C., et al. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:4252-4257.
15. Department of Health and Human Services. Cancer therapy evaluation program, common terminology criteria for adverse events, v.3.0. DHHS; 2006. [accessed 28 May 2009]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.